Hua Medicine Starts New US Combination Trial of GKA Diabetes Candidate
publication date: Apr 23, 2019
Hua Medicine of Shanghai has started a US Phase I trial of its lead drug, dorzagliatin, a first-in-class oral glucokinase activator (GKA), in patients with type 2 diabetes not controlled by metformin, a DPP-4 inhibitor or a SGLT2 inhibitor. The trial will test the PK/PD of dorzagliatin together with empagliflozin, the Boehringer Ingelheim SGLT2 inhibitor known as Jardiance. The trial's endpoints are pharmacokinetic interaction between the two molecules, plus safety and tolerability of the combination. More details....
Stock Symbol: (HK: 2552)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.